Cardinal Health's stock falls after company says contract with OptumRx will not be renewed after June
By Ciara Linnane
Drug distributor backs fiscal 2024 profit guidance despite end of contract that generated 16% of its revenue last year
Cardinal Health Inc.'s stock fell 4% early Monday, after the drug distributor and medical-laboratory products maker said its contracts with pharmacy-benefits manager OptumRx will expire at the end of June and will not be renewed.
The Dublin, Ohio-based company said it still expects 2024 EPS of $7.20 to $7.35 despite the end of the contract, which generated 16% of its revenue in fiscal 2023.
"We have plans in place to continue delivering profitable growth in fiscal 2025, and we are pleased to reaffirm our long-term targets for the pharmaceutical and specialty solutions segment and enterprise, despite this nonrenewal," Chief Executive Jason Hollar said in a statement.
The company reiterated its pharmaceutical and specialty solutions long-term segment profit compound annual growth rate (CAGR) target of 4% to 6% and its consolidated adjusted per-share earnings CAGR target of 12% to 14% for fiscal 2024 to 2026.
Cardinal Health has not yet offered guidance for fiscal 2025 but expects growth in both segments and to achieve an adjusted profit. It expects to offset the loss of the OptumRx contract with new customer wins, specialty growth and other actions.
About 90% of its 2023 sales to OptumRx were non-specialty bulk shipments to the company's mail-dispensing facilities, which had a "meaningfully lower operating margin" than the overall pharma and specialty-solutions segment.
Cardinal Health is expecting to generate adjusted free cash flow of about $2 billion on average from fiscal 2024 to 2026, although it does expect the metric to be lower than average in fiscal 2024 as the OptumRx deal unwinds.
The stock (CAH) has gained 2.7% in the year to date, while the S&P 500 has gained 4%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-22-24 0946ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now